A Genetic Immunization Adjuvant System Based on BVP22–Antigen Fusion
- 1 July 2001
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 12 (10) , 1353-1359
- https://doi.org/10.1089/104303401750271002
Abstract
DNA vaccines must induce a greater immune response to be effective in the biomedical industry. Therefore, we tested the trafficking trait of the bovine herpesvirus 1 (BHV-1) protein VP22 (BVP22) fused to an antigen and applied this unique trait to genetic immunization. DNA immunization with BVP22–antigen stimulates immune responses superior to that of standard DNA immunization. Mice were injected intramuscularly with gene constructs expressing the antigen yellow fluorescent protein (YFP), YFP fused to BVP22, or YFP fused to BHV-1 tegument protein VP16 (BVP16). The results revealed a significantly enhanced YFP antibody response with BVP22-YFP DNA immunization compared with either YFP or BVP16–YFP gene immunization. Notably, the BVP22-YFP DNA construct induced a stronger T helper 1 (Th1) response, based on IFN-γ and IL-4 cytokine levels, and IgG2a/IgG1 ratios. Furthermore, BVP22–YFP genetic immunization induced a greater cytotoxic T lymphocyte response. The genetic adjuvant properties of BVP22 can make DNA vaccines much more effective clinically.Keywords
This publication has 23 references indexed in Scilit:
- Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Linkage of Herpes Simplex Virus Type 1 VP22 Protein to AntigenJournal of Virology, 2001
- Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic ApplicationsThe International Journal of Cell Cloning, 2000
- Quantification of VP22‐GFP spread by direct fluorescence in 15 commonly used cell linesThe Journal of Gene Medicine, 1999
- Immune response to green fluorescent protein: implications for gene therapyGene Therapy, 1999
- Intercellular trafficking of VP22-GFP fusion proteinsGene Therapy, 1999
- DNA Vaccines: A ReviewPublished by Elsevier ,1999
- Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22Gene Therapy, 1999
- Intercellular delivery of functional p53 by the herpesvirus protein VP22Nature Biotechnology, 1998
- DNA VACCINESAnnual Review of Immunology, 1997
- Cd8+ lymphocytes that kill allogeneic and xenogeneic major histocompatibility complex class I targetsHuman Immunology, 1995